Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion.
In the biggest health-care deal in two years, Abbott will pay $105 per common share in cash, the companies said Thursday in a statementBloomberg Terminal. The price represents a 51% premium to Exact Sciences’ closing price on Nov. 18, the last full trading day before Bloomberg reported that Abbott was nearing a deal.
